Supernus stock surges on FDA approval
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) climbed 5.5% Tuesday as the U.S. Food and Drug Administration approved ...
Investing7d
Supernus stock surges on FDA approval
Supernus CEO Jack Khattar expressed the company's commitment to developing novel alternatives for managing neurological conditions. In response to the approval, TD Cowen analyst Stacy Ku ...
Neurology Advisor12d
Labeling for ADHD Med Qelbree Updated With Lactation, Pharmacodynamic Data
Commenting on the new labeling, Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals, said, “By expanding Qelbree’s label to include new data on the pharmacodynamics and ...
Yahoo Finance16d
Supernus Pharmaceuticals Inc. R (S49.MU)
Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq ...
FiercePharma7d
Supernus' 4th try proves the charm with long-awaited FDA approval for Parkinson's infusion pump Onapgo
Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...
Yahoo Finance16d
Supernus Pharmaceuticals, Inc. (SUPN)
announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday ...
BioSpace6d
Supernus Taps Potential $300M US Opportunity With FDA Win for Parkinson’s Drug-Device Combo
The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...
Pharm Exec4d
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...